Takeda's CEO Says It Needs to Sell Assets Quickly to Cut Debt
(Bloomberg) -- The sooner, the better.
That's Christophe Weber's time frame for shedding assets as Takeda Pharmaceutical Co. tries to reduce a heavy debt load after completing its $62 billion takeover of Shire Plc. The company has laid out a scenario of a potential $10 billion in divestments in an effort to deleverage.
“It will come as it goes, but we want to move with speed,” said the Japanese drugmaker's chief executive officer in an interview Tuesday during the JPMorgan Healthcare Conference in San Francisco.
Weber needs to move fast. For one, debt is a huge issue, with net borrowings more than doubling as Takeda takes on about $30 billion in debt to acquire Shire. S&P Global Ratings downgraded Takeda on Tuesday, questioning how quickly it will be able to repair worsening financial ratios.
In addition, Weber needs to whip the new Takeda into shape as competition heats up in the pharmaceutical industry. This year has already seen an explosion of deals, highlighted by Bristol-Myers Squibb Co.'s $74 billion agreement to buy Celgene Corp.
Read more: How Takeda's $62 Billion Shire Deal Reshapes Pharma World
Takeda said it's looking to divest overseas businesses where the company isn't an industry leader and doesn't have critical mass in the market.
“Some of these products are non-core for us, but might be core for others,” Weber said.
Takeda shares climbed as much as 4.1 percent in early trading in Tokyo Wednesday, rising for a fourth day. The stock fell 42 percent last year.
--With assistance from Lisa Du.
To contact the reporter on this story: Bailey Lipschultz in New York at blipschultz@bloomberg.net
To contact the editors responsible for this story: K. Oanh Ha at oha3@bloomberg.net, Jeff Sutherland
©2019 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.